J.P. Morgan Keeps Their Buy Rating on Erasca (ERAS)

In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Erasca, with a price target of $23.00. The company’s shares closed yesterday at $10.46. C ...

Evercore ISI Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome ASC Inhibitor IC 100 is the next evolution ...

3 Stocks Estimated To Be Trading Below Intrinsic Value By 11.4% To 38.4%

Over the last 7 days, the United States market has experienced a slight decline of 1.0%, yet it remains up by an impressive 23% over the past year, with earnings forecasted to grow by 17% annually. In ...

Agilysys And Two Other Stocks Priced Below Estimated Value

Over the last 7 days, the United States market has experienced a slight decline of 1.0%, yet it remains up by an impressive 23% over the past year, with earnings anticipated to grow by 17% annually.